ImmunArray’s cost-effective early diagnostic and therapy monitoring technology profiles the antibody repertoire in blood, saliva or other body fluids. These profiles will be used for early diagnosis of auto-immune diseases, inflammatory diseases, cancer and other disorders, as well as for selecting the most suitable treatments for, and monitoring therapy responses of individual patients.
Personalized medicine approaches utilize bio-markers for early identification of patients in particular disease subgroups and/or those predisposed to a particular disease. Biomarkers can also facilitate more informed selection and dosing of medicines, thus reducing side effects and improving efficacy. In addition, through improved prediction of the outcomes of drug treatments, physicians are better equipped to decide when to, whether to, and how to treat patients; thereby improving the quality and cost effectiveness of treatment.
Current biomarker-based methods in use for screening and diagnosis of immune-related diseases rely mostly on the measurement of single biomarkers and show limited specificity and sensitivity to their specific disease targets.
ImmunArray’s breakthrough personalized medicine technology, the iCHIP, is based on mining the detailed information stored by an individual's immune system in the form of auto-antibodies; antibodies directed against the body's own molecules. The iCHIP platform detects global patterns of these antibodies binding to a vast number of antigens simultaneously, which may be used to reveal specific changes related to the presence and properties of inflammatory diseases, cancer and other immune-related diseases.